Quick Answer
Harmony Biosciences Holdings, Inc. reported Diluted EPS of $2.71 per share for fiscal year 2025.
Harmony Biosciences Holdings, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $2.71 | +8.0% |
| 2024 | $2.51 | +17.8% |
| 2023 | $2.13 | -28.3% |
| 2022 | $2.97 | +412.1% |
| 2021 | $0.58 | +123.4% |
| 2020 | -$2.48 | +89.7% |
| 2019 | -$24.07 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.87 | +10.1% | +27.9% |
| June 30, 2025 | $0.68 | +240.0% | -12.8% |
| March 31, 2025 | $0.78 | +16.4% | -1.3% |
| September 30, 2024 | $0.79 | +25.4% | +295.0% |
| June 30, 2024 | $0.20 | -64.3% | -70.1% |
| March 31, 2024 | $0.67 | +39.6% | +6.3% |
| September 30, 2023 | $0.63 | -56.2% | +12.5% |
| June 30, 2023 | $0.56 | +43.6% | +16.7% |
- Harmony Biosciences Holdings, Inc. showed an increase of +8.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, Harmony Biosciences Holdings, Inc.’s diluted eps has grown by 111.3% (from $24.07 per share (loss) to $2.71 per share).
- The most recent figure is from Harmony Biosciences Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: